Retinol

1. What conditions has Retinol been studied for?

• Vitamin A deficiency/status assessment and related clinical outcomes: The BOND review focuses on assessing vitamin A status (including clinical/functional indicators related to eye health) and discusses biomarkers such as serum retinol, retinol-binding protein (RBP), breast-milk retinol, dose-response tests, isotope dilution, and serum retinyl esters, with liver vitamin A as a reference standard.

• Skin aging/photoaging (topical retinol): A clinical/biopsy-based comparison study evaluated topical retinol versus topical retinoic acid for skin structural and molecular changes and facial wrinkle appearance.

• Cancer (prevention/biology and therapeutic derivatives): One review discusses relationships between retinol/β-carotene and cancer (noting uncertainty for some in vivo roles), and also discusses anti-cancer actions of vitamin A derivatives (e.g., fenretinide/4-HPR). Another review focuses on CRBP-1 (cellular retinol trafficking) in cancer progression and retinol sensitivity in vitro.

• Promyelocytic leukemia (via retinoic acid, derived from retinol): Retinol is described as a precursor to retinoic acid, which is used therapeutically in promyelocytic leukemia (the abstract emphasizes retinoic acid rather than retinol itself as the treatment).

• Reproductive function / ovarian steroidogenesis: A mechanistic study in porcine and human ovarian granulosa cells links retinol metabolism (retinoic acid synthesis via ALDH1A1/ALDH1A2) to estrogen and progesterone synthesis and granulosa-cell proliferation pathways.

• Metabolic, cardiovascular, developmental and vision-related disorders linked to retinol transport: An RBP4 review describes how defects/mutations in RBP4 can cause conditions affecting embryonic development, vision, metabolism, and cardiovascular diseases due to dysregulated retinoid homeostasis.

• Broad phenotypes via human genetics: A large GWAS and Mendelian randomization phenome-wide study (MR-pheWAS) evaluated genetically proxied circulating retinol in relation to many traits, highlighting signals for inflammation, adiposity, ocular measures, microbiome features, and MRI-derived brain phenotypes.

2. Does it work in treating those conditions? Summarize the evidence.

• Skin aging (topical retinol): Supported for improving wrinkles and skin structure.

  • In the head-to-head study, 4 weeks of topical retinol (and retinoic acid) increased epidermal thickness and upregulated COL1A1 and COL3A1 gene expression with increases in procollagen I/III proteins; effects with retinol were similar in direction but “tend to be smaller” than retinoic acid.

  • In a clinical appearance study, 12 weeks of retinol application produced a significant reduction in facial wrinkles by digital image analysis.

• Promyelocytic leukemia: Evidence in abstracts supports retinoic acid, not retinol directly.

  • The abstract states retinoic acid is used as a therapeutic agent for promyelocytic leukemia; retinol is described as its precursor. No direct clinical evidence for retinol as treatment is provided in the abstracts.

• Cancer prevention/treatment: Suggestive but not established from these abstracts.

  • One review proposes vitamin A nutritional management may help prevent cancer, but also notes that some roles of retinol/β-carotene in vivo are “still unknown,” indicating uncertainty.

  • CRBP-1 review: evidence is largely mechanistic/associational and in vitro—CRBP-1 downregulation is associated with more malignant phenotypes in several cancers, and re-expression increased retinol sensitivity and reduced viability of ovarian cancer cells in vitro. This does not establish clinical efficacy of retinol supplementation.

  • Fenretinide (4-HPR) and other derivatives are discussed as anti-cancer agents, but these are retinoid drugs rather than dietary retinol; clinical effectiveness is not established by the provided abstracts.

• Reproductive function/ovarian steroidogenesis: Mechanistic support, not clinical treatment evidence.

  • Retinoic acid (a metabolite of retinol) strengthened estrogen and progesterone synthesis in granulosa cells, and ALDH1A1-driven retinoic acid synthesis influenced proliferation and steroidogenesis pathways. This supports biological plausibility, but it is not evidence that retinol supplementation treats infertility or reproductive disorders in humans.

• Inflammation/adiposity/other traits (genetic evidence): Hypothesis-generating, not proof of treatment benefit.

  • The MR-pheWAS “suggests” potential causal effects of retinol on inflammation, adiposity, ocular measures, microbiome, and brain MRI phenotypes, but Mendelian randomization is not equivalent to clinical trial evidence and can be affected by assumptions/pleiotropy.

3. What health benefits does it have?

• Vision and eye health: Vitamin A status is linked to functional indicators related to eye health (BOND review). Retinol derivatives are described as fundamental for vision, and retinol is oxidized to retinal for visual function.

• Skin health and anti-aging effects (topical): Topical retinol increased epidermal thickness and collagen-related gene/protein expression and reduced facial wrinkles over 12 weeks in the cited study.

• Immune function and general essential roles: Retinol/vitamin A is described as essential across the lifespan and important for normal growth, vision, reproduction, and immune function (noted in the provided text and reviews).

• Cell differentiation, proliferation, and tissue remodeling: Retinol and derivatives influence differentiation/proliferation/apoptosis; CRBP-1 is described as important for intracellular retinol handling and is implicated in wound healing and arterial tissue remodeling.

• Reproductive hormone biology (mechanistic): Retinol metabolism to retinoic acid is implicated in supporting estrogen and progesterone synthesis in ovarian granulosa cells and related proliferation signaling pathways (mechanistic evidence).

• Potential antioxidant/oxidative stress-related roles (more established for carotenoids; broader retinoid context): A review describes antioxidant functions of retinoids and carotenoids (e.g., quenching singlet oxygen, stabilizing free radicals), while also noting complexities such as oxidative metabolites and interactions with lipoxygenases.

4. Does it have any downsides or side effects?

• Toxicity risk at high exposure (systemic vitamin A)

  • The BOND review notes serum retinol is under homeostatic control “in part” because of vitamin A’s toxic properties at high concentrations, implying excess intake can be harmful (though specific adverse events are not detailed in the abstract).

• Assessment pitfalls during infection/inflammation (biomarker limitation with clinical implications)

  • Serum retinol concentrations are depressed during infection and inflammation because RBP is a negative acute-phase reactant, which can lead to misclassification of vitamin A status if inflammation is not accounted for.

• Teratogenicity risk (retinoids, especially long-term use)

  • A review of retinol/retinoid-related compounds notes that despite therapeutic benefits, long-term use carries risks such as teratogenicity. (The abstract discusses retinoids broadly; it does not isolate the risk to retinol alone, and risk depends on compound, dose, and route.)

• Genetic/transport defects can dysregulate retinoid homeostasis

  • Mutations/defects in RBP4 can cause disease due to dysregulated retinoid homeostasis (developmental, vision, metabolic, cardiovascular). This is not a “side effect” of retinol per se, but it indicates that altered transport biology can change risk/response.

• Limitations of the provided abstracts

  • The topical retinol study abstract does not detail adverse events (e.g., irritation), and the systemic safety profile (e.g., hypervitaminosis A) is not quantified in these abstracts. Therefore, side-effect conclusions are limited to what is explicitly stated.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

• RBP4 mutations/defects (retinol transport): likely clinically important

  • RBP4 is the specific transport protein for retinol in blood; defects/mutations in RBP4 can cause a variety of conditions (embryonic development, vision, metabolism, cardiovascular diseases) due to dysregulated retinoid homeostasis. This implies that individuals with such variants may have altered distribution/availability of retinol and may respond differently to intake or therapy, though the abstract does not provide treatment guidance.

• Genetic determinants of circulating retinol (GWAS/MR): variants may influence baseline levels and possibly downstream traits

  • A GWAS (up to 22,274 participants) identified eight common variant loci and a rare-variant signal associated with circulating retinol, including genes beyond the main transport complex (RBP4:TTR) related to lipid biology, energy homeostasis, and endocrine signaling.

  • Using genetic proxies, an MR-pheWAS suggested potential causal links between retinol and traits including inflammation, adiposity, ocular measures, microbiome, and brain MRI phenotypes; it also suggested retinol may be causally influenced by lipids and serum creatinine. These findings are best viewed as prioritization signals rather than definitive pharmacogenomic prescribing rules.

  • The study also suggests a retinol polygenic score could identify individuals more likely to fall outside normative circulating retinol ranges for age—potentially useful for risk stratification, but not yet validated as a tool to guide supplementation dose or predict adverse effects.

• Intracellular trafficking (CRBP-1): potential modifier of retinol sensitivity in cancer biology (early-stage evidence)

  • CRBP-1 downregulation is associated with more malignant phenotypes in several cancers, and CRBP-1 reexpression increased retinol sensitivity and reduced ovarian cancer cell viability in vitro. This suggests CRBP-1 status could modify cellular response to retinol/retinoids, but clinical pharmacogenomic utility is not established in the abstracts.

• Retinoic acid synthesis genes (ALDH1A1/ALDH1A2): plausible modifiers of retinol-to-retinoic-acid conversion

  • In granulosa cells, retinoic acid synthesis was dominated by ALDH1A1 and required assistance of ALDH1A2, linking these enzymes to steroidogenesis pathways. While not presented as human genetic association data, it supports biological plausibility that variants affecting these enzymes could alter retinoid signaling and downstream physiology.

References

1. Biomarkers of Nutrition for Development (BOND)-Vitamin A Review.
   Sherry A Tanumihardjo, Robert M Russell, Charles B Stephensen, Bryan M Gannon, Neal E Craft, Marjorie J Haskell, Georg Lietz, Kerry Schulze, Daniel J Raiten (2016) - The Journal of nutrition
2. Vitamin A in health care: Suppression of growth and induction of differentiation in cancer cells by vitamin A and its derivatives and their mechanisms of action.
   Noriko Takahashi, Daisuke Saito, Shinya Hasegawa, Masahiro Yamasaki, Masahiko Imai (2022) - Pharmacology & therapeutics
3. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin.
   Rong Kong, Yilei Cui, Gary J Fisher, Xiaojuan Wang, Yinbei Chen, Louise M Schneider, Gopa Majmudar (2016) - Journal of cosmetic dermatology
4. Retinoid Homeostasis and Beyond: How Retinol Binding Protein 4 Contributes to Health and Disease.
   Julia S Steinhoff, Achim Lass, Michael Schupp (2022) - Nutrients
5. Genetic influences on circulating retinol and its relationship to human health.
   William R Reay, Dylan J Kiltschewskij, Maria A Di Biase, Zachary F Gerring, Kousik Kundu, Praveen Surendran, Laura A Greco, Erin D Clarke, Clare E Collins, Alison M Mondul, Demetrius Albanes, Murray J Cairns (2024) - Nature communications
6. Retinoic acid enhances ovarian steroidogenesis by regulating granulosa cell proliferation and MESP2/STAR/CYP11A1 pathway.
   Shuang Cai, Meixia Chen, Bangxin Xue, Zhekun Zhu, Xinyu Wang, Jie Li, Huakai Wang, Xiangzhou Zeng, Shiyan Qiao, Xiangfang Zeng (2024) - Journal of advanced research
7. Therapeutic Uses of Retinol and Retinoid-Related Antioxidants.
   Janka Vašková, Marek Stupák, Martina Vidová Ugurbaş, Jozef Židzik, Helena Mičková (2025) - Molecules (Basel, Switzerland)
8. Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins.
   Elena Doldo, Gaetana Costanza, Sara Agostinelli, Chiara Tarquini, Amedeo Ferlosio, Gaetano Arcuri, Daniela Passeri, Maria Giovanna Scioli, Augusto Orlandi (2015) - BioMed research international
9. The Extraction of β-Carotene from Microalgae for Testing Their Health Benefits.
   Jing Wang, Xinge Hu, Junbin Chen, Tiannan Wang, Xianju Huang, Guoxun Chen (2022) - Foods (Basel, Switzerland)
10. Retinoids in health and disease: A role for hepatic stellate cells in affecting retinoid levels.
    Maya W Haaker, Arie B Vaandrager, J Bernd Helms (2020) - Biochimica et biophysica acta. Molecular and cell biology of lipids
11. The synergistic effect of retinyl propionate and hydroxypinacolone retinoate on skin aging.
    Qianqian Wang, Fan Hu, Xiaoyun Hu, Yicheng Xie, Le Du, Rui Ye (2023) - Journal of cosmetic dermatology
12. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Jun Han, Min-Lu Han, Hao Xing, Zhen-Li Li, Dao-Yi Yuan, Han Wu, Han Zhang, Ming-da Wang, Chao Li, Lei Liang, Yan-Yan Song, Ai-Jing Xu, Meng-Chao Wu, Feng Shen, Ying Xie, Tian Yang (2020) - International journal of cancer
13. Functions of Intracellular Retinoid Binding-Proteins.
    Joseph L Napoli (2016) - Sub-cellular biochemistry
14. Retinol metabolism signaling participates in microbiota-regulated fat deposition in obese mice.
    Hui Han, Shunfen Zhang, Mengyu Wang, Bao Yi, Yong Zhao, Martine Schroyen, Hongfu Zhang (2025) - The Journal of nutritional biochemistry
15. Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk.
    Catarina Schiborn, Daniela Weber, Tilman Grune, Ronald Biemann, Susanne Jäger, Natascha Neu, Marie Müller von Blumencron, Andreas Fritsche, Cornelia Weikert, Matthias B Schulze, Clemens Wittenbecher (2022) - Circulation research
16. Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study.
    Jiunn Song, Z Gordon Jiang (2023) - Hepatology communications
17. Comparison of five retinoids for anti-photoaging therapy: Evaluation of anti-inflammatory and anti-oxidative activities in vitro and therapeutic efficacy in vivo.
    Peng Shu, Ling Jiang, Menggeng Li, Yi Li, Zhengqiang Yuan, Li Lin, Ju Wen, Haji Akber Aisa, Zhiyun Du (2024) - Photochemistry and photobiology
18. Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.
    Faith Stevison, Jing Jing, Sasmita Tripathy, Nina Isoherranen (2015) - Advances in pharmacology (San Diego, Calif.)
19. Is beta-carotene consumption associated with thyroid hormone levels?
    Bahareh Farasati Far, Nima Broomand Lomer, Hossein Gharedaghi, Hadi Sahrai, Golnaz Mahmoudvand, Arian Karimi Rouzbahani (2023) - Frontiers in endocrinology
20. Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development.
    Noheul Kim, Ronny Priefer (2021) - European journal of medicinal chemistry